| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
To elucidate the poorer differentiation and prognosis of inflammatory bowel disease related tumor, we analyzed the association of biomarker OLMF4. OLFM4 binds frizzled-7, which would lead the suppression of WNT/beta-catenin pathway. OLMF4 was secreted in exosome, and exosomal OLMF4 inhibited the expression of activated form of beta-catenin and EMT markers. Expression of OLMF4 in inflammatory foci of UC-related tumors was reduce along with the tumorigenesis, which suggests the relationship with the malignancy of tumors. It is possible that suppression of EMT by OLMF4 secreted in exosome would be the cause of the malignant potential of IBD related tumor.
|
